FDA recall record

Chlorpheniramine Maleate 4 mg tablets, 24-count bottle recall — FDA D-0029-2025

Superpotent Drug: Stability failure for assay at 6 months test time-point.

Class IIclassification
D-0029-2025official record ID
Nov 6, 2024report date

Recall record at a glance

Official recordD-0029-2025
CategoryDrug Recalls
ClassificationClass II
FDA record statusTerminated
Recalling firmBLI International, Inc.
Report dateNov 6, 2024
Recall initiation dateOct 21, 2024
Quantity4,901 cases/24 count each case
LocationDeer Park, NY, United States

Official product description

Chlorpheniramine Maleate 4 mg tablets, 24-count bottle, Manufactured For: Athlete's Needs, Novi, MI 48377, NDC 53185-277-24

Why the product was recalled

Superpotent Drug: Stability failure for assay at 6 months test time-point.

Distribution information

Product was shipped to two private label customers ( OH & MO) as a final packaged product.

How to read the classification

FDA Class II indicates a situation in which use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious consequences is remote. The classification shown here comes from the FDA record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.